OTXL’s COO, Beth White, notes that the CGTxchange platform could revitalise CGT programmes that would otherwise have been indefinitely put on ice.
ASCGT and OTXL have launched a marketplace for shelved CGT assets. Credit: Net Vector / Shutterstock.com.
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an artificial intelligence (AI)-enabled marketplace for shelved cell and gene therapy (CGT) products.
The pair have designed the new platform, named CGTxchange, to bring together academics, investors, biotechs and non-profit CGT developers in the hope of reinvigorating development programmes for previously discarded assets, many of which were pigeonholed due to funding, rather than safety or efficacy reasons, OTXL’s COO, Beth White, tells Pharmaceutical Technology. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
